Current Treatment Options in Allergy最新文献

{"title":"Management of Pet Allergies in Children in China","authors":"Ya-Ting Li, Y. Jiang, Haiyang Li, Ling-ping Zhu, Jingwen Zhou, Zhen-yuan Dai, Li-Fen Yang, Qintai Yang, Zhuang-gui Chen","doi":"10.1007/s40521-021-00279-x","DOIUrl":"https://doi.org/10.1007/s40521-021-00279-x","url":null,"abstract":"","PeriodicalId":36209,"journal":{"name":"Current Treatment Options in Allergy","volume":"8 1","pages":"111 - 119"},"PeriodicalIF":1.1,"publicationDate":"2021-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40521-021-00279-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46373125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Climate Change on the Pollen Allergy and Sporulation of Allergic Fungi","authors":"J. Demain, Young-Jin Choi, Jae-Won Oh","doi":"10.1007/s40521-020-00277-5","DOIUrl":"https://doi.org/10.1007/s40521-020-00277-5","url":null,"abstract":"","PeriodicalId":36209,"journal":{"name":"Current Treatment Options in Allergy","volume":"8 1","pages":"60-73"},"PeriodicalIF":1.1,"publicationDate":"2021-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40521-020-00277-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45013706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Variants Associated With Drug-Induced Hypersensitivity Reactions: towards Precision Medicine?","authors":"I. Doña, R. Jurado-Escobar, N. Pérez‐Sánchez, J. Laguna, J. Bartra, A. Testera-Montes, Rocío Sáenz de Santa María, M. Torres, J. Cornejo‐García","doi":"10.1007/s40521-020-00278-4","DOIUrl":"https://doi.org/10.1007/s40521-020-00278-4","url":null,"abstract":"","PeriodicalId":36209,"journal":{"name":"Current Treatment Options in Allergy","volume":"8 1","pages":"42 - 59"},"PeriodicalIF":1.1,"publicationDate":"2021-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40521-020-00278-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45156553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Choosing the Optimal Self-Injector Epinephrine","authors":"A. Macías-Weinmann, S. González-Díaz, J. Canseco-Villarreal, R. Guzmán-Avilán, Valeria González, A. Noyola","doi":"10.1007/s40521-020-00276-6","DOIUrl":"https://doi.org/10.1007/s40521-020-00276-6","url":null,"abstract":"","PeriodicalId":36209,"journal":{"name":"Current Treatment Options in Allergy","volume":"1 1","pages":"1-8"},"PeriodicalIF":1.1,"publicationDate":"2021-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40521-020-00276-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46820235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of Bruton's Tyrosine Kinase Inhibitors to Treat Allergic Disorders.","authors":"Melanie C Dispenza","doi":"10.1007/s40521-021-00286-y","DOIUrl":"https://doi.org/10.1007/s40521-021-00286-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>Studies show that inhibitors of Bruton's tyrosine kinase (BTKis), currently FDA-approved for the treatment of B cell malignancies, can prevent IgE-mediated reactions through broad inhibition of the FcεRI signaling pathway in human mast cells and basophils. This review will summarize recent data supporting the use of these drugs as novel therapies in various allergic disorders.</p><p><strong>Recent findings: </strong>Recent studies have shown that BTKis can prevent IgE-mediated degranulation and cytokine production in primary human mast cells and basophils. Two oral doses of the second-generation BTKi acalabrutinib can completely prevent moderate passive systemic anaphylaxis in humanized mice and even protect against death during severe anaphylaxis. Furthermore, two doses of ibrutinib can reduce or eliminate skin prick test responses to foods and aeroallergens in allergic subjects. BTKis in development also show efficacy in clinical trials for chronic urticaria. Unlike other therapies targeting IgE, such as omalizumab, BTKis appear to have rapid onset and transient effects, making them ideal candidates for intermittent use to prevent acute reactions such as IgE-mediated anaphylaxis.</p><p><strong>Summary: </strong>These studies suggest that BTKis may be capable of preventing IgE-mediated anaphylaxis, paving the way for future trials in food allergy and urticaria.</p>","PeriodicalId":36209,"journal":{"name":"Current Treatment Options in Allergy","volume":"8 3","pages":"261-273"},"PeriodicalIF":1.1,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40521-021-00286-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38894279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Anaphylaxis During the SARS-CoV-2 Pandemic.","authors":"Kanwaljit K Brar, Albana Harizaj, Anna Nowak-Wegrzyn","doi":"10.1007/s40521-021-00284-0","DOIUrl":"10.1007/s40521-021-00284-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>Management of anaphylaxis during the SARS-CoV-2 pandemic should consider local infection rates so as to not burden local ED at times of pandemic, while also protecting patients from infection risks and progression of anaphylaxis. In this review, we identify a treatment strategy for anaphylaxis that balances the risks versus benefits of ED versus home management in this unprecedented time.</p><p><strong>Recent findings: </strong>Physicians and patients have had to adapt new approaches to medical care during the SARS-CoV-2 pandemic due to restricted access to health care facilities. Telemedicine has substituted in-person visits, and such a drastic change in the patient care paradigm presents a need to revise the acute management of anaphylaxis.</p><p><strong>Summary: </strong>Physicians should utilize telemedicine during this time to engage in shared decision-making with patients and their families to devise an anaphylaxis plan of management that emphasizes home care when symptoms are mild with an exception for ED care if a patient has had severe, near-fatal anaphylaxis episodes in the past. Previous anaphylaxis recommendations should remain in place despite the pandemic, including prompt use of epinephrine when needed, avoidance of known allergens, training of patients and their caregivers, and carrying of epinephrine autoinjector devices at all times to remain prepared in the event of an anaphylaxis episode.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40521-021-00284-0.</p>","PeriodicalId":36209,"journal":{"name":"Current Treatment Options in Allergy","volume":"8 2","pages":"88-96"},"PeriodicalIF":1.9,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25481694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patients' Perspectives and Needs on Novel Food Allergy Treatments in the United States.","authors":"Linda Herbert, Mary Jane Marchisotto, Brian Vickery","doi":"10.1007/s40521-020-00274-8","DOIUrl":"10.1007/s40521-020-00274-8","url":null,"abstract":"<p><strong>Purpose: </strong>Food allergy management places a daily psychosocial burden on patients and their caregivers. New food allergy treatments may positively impact their lives, but also introduce new stressors. The purpose of this paper is to provide an overview of the current state of the literature regarding patients' and caregivers' food allergy experiences and needs within the United States as well as a set of recommendations regarding how best to proceed with patient-centered development and evaluation of new food allergy treatments.</p><p><strong>Recent findings: </strong>The first pharmaceutical-grade product for peanut oral immunotherapy was approved in the United States for children aged 4-17 years following a successful international Phase 3 trial. This new treatment is only the first of several food allergy treatments currently under development. Patients will soon be presented with multiple options for food allergy treatment and will need to make decisions about what treatment is best for them.</p><p><strong>Summary: </strong>Allergy researchers and providers are encouraged to consider patients' perspectives and needs when developing and evaluating new food allergy treatments. Recommendations regarding next steps include the development of new patient-reported outcome tools, focus on psychosocial support, health disparities, and financial implications, and research harmonization and interdisciplinary collaboration.</p>","PeriodicalId":36209,"journal":{"name":"Current Treatment Options in Allergy","volume":"8 1","pages":"9-20"},"PeriodicalIF":1.9,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825384/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10683674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of the Environment and Exposome in Atopic Dermatitis.","authors":"Nicholas Stefanovic, Alan D Irvine, Carsten Flohr","doi":"10.1007/s40521-021-00289-9","DOIUrl":"10.1007/s40521-021-00289-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>Atopic dermatitis (AD) is a chronic inflammatory skin disorder affecting up to 20% of children and up to 5% of adults worldwide, contributing to significant disease-related morbidity in this patient cohort. Its aetiopathogenesis is underpinned by multiple factors, including genetic susceptibility, skin barrier defects, a skewed cutaneous immune response and microbiome perturbation in both the skin and the gut. In this review, we aim to examine the biological effects of key environmental exposures (the sum of which is termed the \"exposome\") at the population, community and individual levels in order to describe their effect on AD pathogenesis.</p><p><strong>Recent findings: </strong>It is now understood that as well as considering the type of environmental exposure with regard to its effect on AD pathogenesis, the dosage and timing of the exposure are both critical domains that may lead to either exacerbation or amelioration of disease. In this review, we consider the effects of population-wide exposures such as climate change, migration and urbanization; community-specific exposures such as air pollution, water hardness and allergic sensitisation; and individual factors such as diet, microbiome alteration, psychosocial stress and the impact of topical and systemic therapy.</p><p><strong>Summary: </strong>This review summarises the interaction of the above environmental factors with the other domains of AD pathogenesis, namely, the inherent genetic defects, the skin barrier, the immune system and the cutaneous and gut microbiota. We specifically emphasise the timing and dosage of exposures and its effect on the cellular and molecular pathways implicated in AD.</p>","PeriodicalId":36209,"journal":{"name":"Current Treatment Options in Allergy","volume":"8 3","pages":"222-241"},"PeriodicalIF":1.9,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39034446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Latest Developments in the Management of Nut Allergies.","authors":"H A Brough,&nbsp;R Gourgey,&nbsp;S Radulovic,&nbsp;J C Caubet,&nbsp;G Lack,&nbsp;A Anagnostou","doi":"10.1007/s40521-021-00290-2","DOIUrl":"https://doi.org/10.1007/s40521-021-00290-2","url":null,"abstract":"<p><strong>Purpose of review: </strong>In this review, we sought to describe the most recent advances in the dietary and medical management of peanut and tree nut allergy, including selective introduction and immunotherapy.</p><p><strong>Recent findings: </strong>Dietary updates include changes to labeling laws, improved information sources, and new apps for buying foods in shops and overseas to better protect individuals with nut allergies. There are still issues in the management of nut allergies in schools, such as parents having to resort to packed lunches instead of school meals and patients experiencing bullying. Air travel also poses concern, but additional resources are now available to travelers, and recent evidence suggest limited airborne exposure to nuts. The medical management of anaphylaxis is use of epinephrine; however, this remains underutilized. Needle length and administration devices have been recently debated considering the risk of bone penetration vs subcutaneous administration, and autoinjectors seem to deliver higher peak concentrations than syringes. Selective nut introduction has gained momentum in the last 5 years, demonstrating improved quality of life but with the need for motivated parents for continued consumption and available resources for challenges. Immunotherapy to nuts is also a rapidly developing field, with the balance of efficacy and safety being important considerations in the differing modes of administration.</p><p><strong>Summary: </strong>The management of nut allergies is a rapidly developing field, and dietary and medical management have progressed significantly in the last 5 years. Future research directions include improving safety and efficacy of food immunotherapy and examining patients' goals for therapy and treatment outcomes.</p>","PeriodicalId":36209,"journal":{"name":"Current Treatment Options in Allergy","volume":"8 2","pages":"97-110"},"PeriodicalIF":1.1,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40521-021-00290-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39250319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ubiquity, Hazardous Effects, and Risk Assessment of Fragrances in Consumer Products.","authors":"María-Antonia Pastor-Nieto,&nbsp;María-Elena Gatica-Ortega","doi":"10.1007/s40521-020-00275-7","DOIUrl":"https://doi.org/10.1007/s40521-020-00275-7","url":null,"abstract":"<p><strong>Purpose of review: </strong>The main aims of fragrances are to create pleasing scents or to mask unpleasant odors. We hereby review their main exposure sources, presumed benefits, and unwanted effects, with special attention to allergic contact dermatitis (prevalence, regulatory environment, risk assessment methodology, and preventive measures).</p><p><strong>Recent findings: </strong>Fragrances elicit positive emotions and presumably have therapeutic benefits related to stress reduction and memory enhancement. However, they also cause detrimental health or environmental effects including contact dermatitis (irritant and/or allergic), non-eczematous contact reactions, photosensitivity, photo-allergy, and immediate contact reactions, which can negatively impact the quality of life. Fragrances are the most frequent chemicals causing contact dermatitis. Their main sources are cosmetics, household products, industrial substances, food flavorings, oral hygiene products, and topical medications. It is difficult for sensitized patients to avoid contact with fragrances, due to their ubiquity and because manufacturers are not willing to volunteer information regarding fragrance ingredients.</p><p><strong>Summary: </strong>The treatment of contact dermatitis relies on allergens avoidance which does not \"cure\" the disease (sensitization persists for life) but prevents disabling illness. The patient should understand that avoiding perfume means to avoid all scented goods and not just perfumes.Labeling fragrances is key in primary prevention (by giving the healthy individual the chance to make an informed choice to avoid risky substances), diagnosis (by helping the practitioner to plan and interpret patch tests), secondary prevention, and prognosis (by allowing the sensitized patient to follow the avoidance instructions). However, only 26 fragrances are mandatory to be declared in cosmetics. The vague labeling of other fragrance ingredients as \"perfume\" or \"fragrance\" hampers the diagnostic and preventive approaches. Therefore, in our opinion, declaration should be mandatory for all fragrance ingredients as well as straightforward so most consumers can understand it. Moreover, legislation should be improved to prevent inappropriately high exposures by forbidding stronger allergens, restricting maximum concentrations in the finished product or fields of application, delivering information regarding the risks to the general public, and controlling the compliance of manufacturers with the regulations. Besides, manufacturers should share information regarding the composition in the final products and provide physicians with samples of all fragrance chemicals whenever needed for patch test investigations.</p>","PeriodicalId":36209,"journal":{"name":"Current Treatment Options in Allergy","volume":" ","pages":"21-41"},"PeriodicalIF":1.1,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40521-020-00275-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25316042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}